Investment & M&A transaction comps
Healthcare Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged healthcare. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 27
- With value data
- 7
- With revenue multiples
- 3
- Transaction years
- 2016–2026
Sortable transaction comps
Healthcare transaction table
Rows with reported value
5 / 25
Acquisition EV, USD
USD 7.2B
Investment EV, USD
-
Median EV / revenue
3.7x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
25 shown of 27 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sohar Health Control | 2026-10-14 | Zocdoc | Undisclosed | Undisclosed | - | - | New York, USA | Confirmed 2 sources | ||
| Sofie Biosciences Control | 2026-10-05 | GE HealthCare | USD 945M Enterprise Value | 945 | - | - | United States | Confirmed 3 sources | ||
| IMATS Control | 2026-09-22 | Command Medical | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | ||
| Vyne Medical Control | 2026-09-16 | MRO | Undisclosed | Undisclosed | - | - | United States | Confirmed 2 sources | ||
| 2026-08-26 | CoreHealth Technologies | Undisclosed Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| Circulate Health Control | 2026-08-12 | Viome | Undisclosed | Undisclosed | - | - | United States | Confirmed 2 sources | ||
| E-Pharma Trento Control (100%) | 2026-08-07 | Wise Equity | Undisclosed | Undisclosed | - | - | Italy | Confirmed 1 source | ||
| Texas MedClinic Control | 2026-08 | HCA Healthcare | Undisclosed | Undisclosed | - | - | Texas, United States | Confirmed 1 source | ||
| BIO-CAT Enzymes & Microbials Control | 2026-07-31 | Lallemand Inc. | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| Avanos Medical, Inc. Control | 2026-07-27 | American Industrial Partners | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| 2026-07-20 | Eurofins | Undisclosed | Undisclosed | - | - | North America | Confirmed 1 source | |||
| Spire Healthcare portfolio Control | 2026-07-08 | Funds managed by Blue Owl Capital | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| 2026-07-06 | Altaris LLC | USD 600M Consideration | 600 | - | - | - | Confirmed 1 source | |||
| Bio-Techne Control | 2026-06-25 | Merck KGaA, Darmstadt, Germany | Undisclosed | Undisclosed | - | - | United States / Germany | Confirmed 1 source | ||
| 2026-05-27 | HCA Healthcare | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| SPR Therapeutics Control | 2026-05-20 | Medtronic | Undisclosed Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Cross Country Healthcare Control | 2026-05 | Knox Lane | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Tally Health Control | 2026-04-29 | Infinite Epigenetics | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | ||
| 2026-04-27 | Astorg | USD 1.1B Consideration | 1,075 | - | - | - | Confirmed 1 source | |||
| CathWorks Control | 2026-04-20 | Medtronic | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Amplitude Vascular Systems Control | 2026-04-13 | Stryker | USD 835M Consideration | 835 | - | - | United States | Confirmed 2 sources | ||
| Clario Holdings, Inc. Control | 2025-10-29 | Thermo Fisher Scientific | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Tianjin TSKF Pharmaceutical Co., Ltd. Control (12%) | 2025-06-27 | Haleon plc | Undisclosed | Undisclosed | - | - | China | Confirmed 9 sources | ||
| Tianjin TSKF Pharmaceutical Co. Ltd (TSKF) Control (33%) | 2024-09-27 | Haleon | Undisclosed | Undisclosed | - | - | China | Estimated 10 sources | ||
| 2018-04-19 | The Procter & Gamble Company | USD 3.7B Enterprise Value | 3,700 | 3.7x | 17.2x | Global | Estimated 5 sources |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.